治療方法が局所的に進行した胃がんに与える影響 - 現実世界データ
1Adıyaman Training and Research Hospital Medical Oncology Department, Adiyaman 02040, Turkey.
Current oncology (Toronto, Ont.)
|August 27, 2025
まとめ
局所的に進行した胃がんでは,アジュバント化学療法 (ACT) はネオアジュバント化学療法 (NACT) よりも長い生存期間を示した. しかし,化学療法のタイミングではなく,患者の選択とベースラインの違いがこれを説明し,さらなるランダム化試験が必要である.
科学分野:
- 腫瘍学
- 胃腸腫瘍学
- 臨床がん研究
背景:
- 局所的に進行した胃がん (LAGC) の化学療法の最適なタイミングは議論されています.
- 補助化学療法 (ACT) と新補助化学療法 (NACT) の比較は,治療戦略において極めて重要です.
研究 の 目的:
- LAGC患者におけるACTとNACTの生存結果 (PFS,OS) を比較する.
- 現実の世界での生存に影響を与える臨床病理学的要因を特定する.
主な方法:
- 103人のLAGC患者 (2014年から2024年) の遡及分析.
- ACT (n=56) とNACT (n=47) に分類する.
- カプラン・マイヤーとコックス回帰による生存と予後因子評価
主要な成果:
- NACTグループ:若い,近隣の腫瘍 平均OS:ACT 48. 7ヶ月対NACT 17. 7ヶ月 (p=0. 048) PFSの中央値:ACT未達成対NACT15. 6ヶ月 (p=0. 008)
- 外科手術のマイナス率と若い年齢は 生存のための独立した予後要因でした.
- NACT患者の21%は,進行または不耐性のために手術を受けませんでした.
結論:
- 観察された生存率の違いは,化学療法の配列ではなく,患者の選択とベースラインの不均衡による可能性が高い.
- NACTの患者を慎重に選ぶ必要があることを強調しています.
- LAGCにおける最適な化学療法配列を確立するために,予期的なランダム化試験の必要性を強調しています.
さらに関連する動画
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
848
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
